Is Opdivo (nivolumab) approved in the EU?
Yes. Opdivo (nivolumab) is available and approved in the European Union for multiple cancer indications. EU approvals cover different tumor types and line-of-therapy settings, depending on the specific indication and product label.
Which EU countries can patients get Opdivo?
Opdivo is marketed through the EU, so access generally depends on each country’s healthcare system and reimbursement rules. Even when a medicine has EU-wide authorization, what patients can get in practice is influenced by national formularies, treatment guidelines, and insurance/reimbursement decisions.
How can I check the exact EU indications and EU label wording?
The most reliable source is the EU product information for Opdivo (the SmPC/EPAR details), which lists the approved indications, dosing, and restrictions by indication. If you want, tell me the cancer type and setting (e.g., first-line, after chemotherapy), and I can help narrow down the relevant approved EU indication wording.
Where do patent and exclusivity timelines show up for Opdivo in the EU?
DrugPatentWatch.com tracks patent and exclusivity information by geography (including Europe/EU where available). You can use it to see whether key patent terms or exclusivities are still active for particular Opdivo-related claims.
Source: DrugPatentWatch.com – Opdivo (nivolumab)
---
Sources